PYRIDYLACETYLENES FOR USE AS RADIOTRACERS AND IMAGING AGENTS

Abstract

The present invention relates to novel pyridylacetylene derivatives, their preparation, their use as radiotracers/markers and compositions containing them.

Description

The present invention relates to novel pyridylacetylene derivatives, their preparation, their use as radiotracers/markers and compositions containing them.

More particularly the invention provides a compound of formula I

wherein

R is CH₃, (CH₂)_nI, (CH₂)_nBr or (CH₂)_nF, n being 1, 2, 3 or 4 in free base or acid addition salt form.

Compounds of the formula I are preferred, wherein

R is ¹¹CH₃, (³H)₃C, (CH₂)_n¹²³I, (CH₂)_n⁷⁶Br or (CH₂)_n¹⁸F, n being 1,2, 3 or 4 in free base or acid addition salt form.

In the case of possible stereoisomerism, e.g. cis/trans-isomerism of double bonds, the compounds can exist as pure stereoisomers or mixtures thereof.

In a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, comprising the steps of

• • a) for the production of a compound of formula Ia

wherein R_a is respectively ¹¹CH₃ or (³H)₃C, reacting the compound of formula II

• • with respectively ¹¹CH₃I or C(³H)₃I, in the presence of a base, or
  • b) for the production of a compound of formula Ib

• • wherein Rb is respectively (CH₂)_n¹⁸F, (CH₂)_n¹²³I or (CH₂)_n⁷⁶Br, reacting a compound of formula III

• • wherein n is as defined above and X is OTs or OMs, with respectively 18F^⊖, ¹²³I^⊖ or ⁷⁶Br^⊖, or reacting the compound of formula II with a compound of formula IV

X—Rb   IV

• • wherein X and Rb are as defined above,

and recovering the resulting compound of formula I in free base form or in form of an acid addition salt.

The reactions can be effected according to known methods, for example as described in the Examples.

Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures.

Acid addition salts may be produced from the free bases in known manner, and vice-versa.

The starting materials of formulae II, III and IV are known or may be obtained in analogous manner to know procedures, e.g. as described in the Examples.

Compounds of formula I in free base or acid addition salt form, hereinafter referred to as agents of the invention, exhibit valuable properties as histopathological labeling agents, imaging agents and/or biomarkers, hereinafter “markers”, for the selective labeling of the metabotropic glutamate receptor subtype 5 (mGlu5 receptor).

More particularly the agents of the invention are useful as markers for labeling the central and peripheral mGlu5 receptors in vitro or in vivo (see Example 5-7).

The agents of the invention are therefore useful, for instance, for determining the levels of receptor occupancy of a drug acting at the mGlu5 receptor, or diagnostic purposes for diseases resulting from an imbalance or dysfunction of mGlu5 receptors, and for monitoring the effectiveness of pharmacotherapies of such diseases.

In accordance with the above, the present invention provides an agent of the invention for use as a marker for neuroimaging.

In a further aspect, the present invention provides a composition for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vivo and in vitro comprising an agent of the invention.

In still a further aspect, the present invention provides a method for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vitro or in vivo, which comprises contacting brain tissue with an agent of the invention.

The method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure. Said further step may be effected by observing the target structure using positron emission tomography (PET) or single photon emission computed tomography (SPECT), or any device allowing detection of radioactive radiations.

The following examples illustrate the invention.

EXAMPLE 1

3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[¹¹C-methyl]-oxime

3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O[¹¹C-methyl]-oxime is synthesized by reacting [¹¹C]-Mel with the sodium salt of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime (1 mg) in dry DMF (400 μl). [¹¹C]-Mel is introduced via a slow stream of helium and when addition is completed the reaction mixture is heated to 120° C. for 10 min. Product purification is accomplished by reversed phase HPLC using a C-18 μ-Bondapak column (7.8×300 mm) and a mobile phase consisting of CH₃CN/0.1% H₃PO₄ (70/30) at a flow rate of 5 ml/min. The retention time of the desired product is between 6 and 7 min.

3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O[¹¹C-methyl]-oxime is formulated in a solution containing polysorbatum (2%), ethanol (10%) and saline (0.9%).

LogD=2.5 (determined using the classical shake-flask method).

The starting materials are prepared as described hereafter:

• • a) 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone

A solution of 2-ethynyl-6-methyl-pyridine (702 mg, 6 mmol), 3-bromo-cyclohex-2-enone (1.26 g, 7.2 mmol), bis-(triphenylphosphine)-palladium-dichloride (168 mg, 0.24 mmol), copper(I) iodide (93 mg, 0.48 mmol), triethylamine (4.8 ml, 34.4 mmol) in 12ml DMF is heated to 55° C. for 1 h. After that time the solution is diluted with ethyl acetate (500 ml) and washed with sat aq. NaHCO₃ (1×150 ml). The water phase is extracted with ethyl acetate (1×150 ml) and the combined organic phases are dried over Na₂SO₄, filtered and concentrated in vacuo. The residue (1.88 g) is purified on column chromatography (silica gel, eluent hexane/ethyl acetate 3:1 v/v) and the fractions containing the desired compound are collected and concentrated in vacuo to yield 1.05 g (yield=82%) of the title compound as a light yellow oil.

• • b) 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime

A solution of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone (422 mg, 2 mmol) and hydroxylamine hydrochloride (278 mg, 4 mmol) in pyridine (20 ml) is stirred for 17 h at RT. After that time the solvent is evaporated in vacuo. The residue is dissolved in ethyl acetate (300 ml) and washed with sat NaHCO₃ (1×50 ml). The water phase is extracted with ethyl acetate (1×50 ml). The combined organic phases are dried over Na₂SO₄, filtered and concentrated in vacuo. The residue (0.45 g) is purified on column chromatography (Silica gel, eluent hexane/ethyl acetate 2:1 v/v) and the fractions containing the desired compound are collected and concentrated in vacuo to yield 0.192 g (yield=42%) of the title compound as light yellow crystals, m.p. 166-168° C.

EXAMPLE 2

3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[tri(³H)-methyl]-oxime

The title compound can be prepared by reacting 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime with [³H]-Mel (0.5 equivalent) in the presence of K₂CO₃ in DMF at 100° C. for 180 min, followed by a purification by reversed phase chromatography.

EXAMPLE 3

3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-(2-[¹⁸F-fluoro]-ethyl)-oxime

The sodium salt of the 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime (2 mg) is reacted in dry DMF (400 μl) with [¹⁸F]-2-fluoro-ethyltosylate (obtained from ethyleneditosylate and [¹⁸F]-KF-Kryptofix complex) at 100° C. for 10 min. The reaction mixture is purified through a tC-18 Sep-Pak cartridge, and the fractions containing the desired product are further purified by a semi-preparative reversed phase HPLC using a C18 Bondclone column (300×7.8 mm) and a mobile phase consisting of CH₃CN/0.01 M H₃PO₄ (70/30) at a flow rate of 4 ml/min. The fraction containing the product (retention time between 12 and 13 min) is passed through a tC-18 Sep-Pak cartridge and eluted with 1 ml of ethanol. This ethanolic solution is buffered with 0.15M phosphate buffer to give after sterile filtration an isotonic and injectable solution.

EXAMPLE 4

3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[¹⁸F-fluoro]-methyl)-oxime

The sodium salt of the 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime (2 mg) is reacted in dry DMF (400 μl) with [¹⁸F]CH₂OTf at 100° C. for 30 min. After an initial purification by passing the reaction mixture through a tC-18 Sep-Pak cartridge, 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[¹⁸F-fluoro]-methyl-oxime was finally purified by a semi-preparative reversed phase HPLC using a C18 Bondclone column (300×7.8 mm) and a mobile phase consisting of CH₃CN/0.01M H₃PO₄ (70/30) at a flow rate of 4 ml/min. The product is formulated in analogy to 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-(2-[18F-fluoro]-ethyl)-oxime (example 3).

EXAMPLE 5

K_i/IC₅₀ Determination (Binding Assay)

In vitro, the affinity for the mGlu5 receptor is determined using a radioligand displacement technique as described by Gasparini et al, Biorg. Med. Chem. Lett. 2002, 12, 407-409. 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-methyl-oxime shows an IC₅₀ of 8 nM (Hill coefficient 1.08; 95% confidence intervals: 6.0-10.0 nM) for the displacement of [³H]-2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine from membrane of L-tk cells stably expressing the human mGlu5 receptor (Daggett et al, Neuropharm. 1995, 34:871-886). Using the Cheng-Prusoff equation, a K_i of 4 nM is calculated (radioligand concentration used for the assay: 2 nM).

EXAMPLE 6

Organ and Brain Structure Distribution

Two groups of male adult Sprague-Dawley rats weighing 250-300 g are used for the biodistribution studies. The first group (n=3) serves as the control group and the second group (n=3) serves as the blockade group. Each animal received 250-300 pmol (0.6-40 MBq) of 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[¹¹C-methyl]-oxime via a lateral tail vein. The blockade group is co-injected with 2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine (1 mg/kg) whereas the control group (n=3) receives a corresponding volume of 0.9% NaCl. The animals are sacrificed 30 min post-injection. Organ or brain regions such as hippocampus, striatum, cortex and cerebellum are removed and measured in a gamma-counter. The tissue distribution is expressed as percentage of injected dose per gram wet tissue (% ID/g organ).

EXAMPLE 7

Results of the Brain Distribution Study with 3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-[¹¹C-methyl]-oxime

The table below displays the percentage of the injected dose normalized per gram of tissue. K1, K2, K3 are individual values for control animals. B1, B2, B3 are individual values for animals co-injected with 2-methyl-6-((3-methoxyphenyl)ethynyl)-pyridine.

Organ	K1	K2	K3	B1	B2	B3
Hippocampus	0.16154	0.25440	0.21264	0.05184	0.06195	0.05972
Striatum	0.22564	0.30685	0.28164	0.06495	0.07158	0.06487
Cortex	0.14849	0.18316	0.16909	0.04964	0.05582	0.05431
Cerebellum	0.03322	0.03925	0.03699	0.04052	0.03608	0.03421
Midbrain	0.07703	0.10559	0.09091	0.03876	0.04700	0.04422
Restbrain	0.05519	0.06520	0.06070	0.03832	0.04762	0.04383
Whole brain	0.11123	0.13659	0.12999	0.04580	0.05118	0.04951

Claims

1. A compound having a structure that is embraced within the genus of formula I in free base or acid addition salt form, and which exhibits activity as an mGluR5 receptor antagonist.

wherein R is 11CH3, (3H)3C, (CH2)n123I, (CH2)n76Br or (CH2)n18F, n being 1,2, 3 or 4;

2. The compound of claim 1, wherein R is 11CH3.

3. The compound of claim 1, wherein R is (3H)3C.

4. The compound of claim 1, wherein R is (CH2)123I.

5. The compound of claim 1, wherein R is (CH2)2123I.

6. The compound of claim 1, wherein R is (CH2)3123I.

7. The compound of claim 1, wherein R is (CH2)4123I.

8. The compound of claim 1, wherein R is (CH2)76Br.

9. The compound of claim 1, wherein R is (CH2)276Br.

10. The compound of claim 1, wherein R is (CH2)376Br.

11. The compound of claim 1, wherein R is (CH2)476Br.

12. The compound of claim 1, wherein R is (CH2)18F.

13. The compound of claim 1, wherein R is (CH2)218F.

14. The compound of claim 1, wherein R is (CH2)318F.

15. The compound of claim 1, wherein R is (CH2)418F.